BioTheryX-17thJan - Clinical Trials Arena
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here

BioTheryX initiates patient dosing in trial of BTX-A51 for AML

The trial will assess the efficacy of BTX-A51 for treating relapsed/refractory AML. Credit: PRNewsfoto/BioTheryX, Inc.